Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure by unknown
Panagopoulos et al. Molecular Cancer 2013, 12:118
http://www.molecular-cancer.com/content/12/1/118RESEARCH Open AccessReversal of chemosensitivity and induction of cell
malignancy of a non-malignant prostate cancer
cell line upon extracellular vesicle exposure
Kiriaki Panagopoulos1†, Sam Cross-Knorr2†, Christen Dillard2, Dionysios Pantazatos1,2, Michael Del Tatto2,
David Mills2, Lisa Goldstein3, Joseph Renzulli4, Peter Quesenberry2 and Devasis Chatterjee2*Abstract
Background: Extracellular vesicle (EV) trafficking is a fundamental cellular process that occurs in cells and is
required for different aspects of pathophysiology. EV trafficking leads to changes in cellular function including
apoptosis, angiogenesis and proliferation required for increased tumor formation.
Results: We report several phenotypic changes mediated by EVs isolated from non-malignant and malignant
prostate cells as well as patient biopsied prostate tumor samples. EVs can reverse the resistance of prostate cancer
cells to camptothecin EVs isolated from non-malignant PrECs (Prostate Epithelial Cells) can reverse soft agar colony
formation of malignant DU145 cells, with the reciprocal effect observed. Isolation of EVs from 2 Gleason grade 8
prostate cancer patients significantly induced soft agar colony formation of non-malignant PrECs. We have
identified proteins via antibody and Mass spectrometry analysis that may be responsible for the phenotypic
changes. Mass spectrometry analysis of protein lysates using ProteoIQ revealed protein candidates associated with
gene ontology annotations that may be responsible for this phenotypic change. Ingenuity Pathway Analysis was
used to identify statistically relevant canonical pathways and functions associated the protein IDs and expression
values obtained using ProteoIQ. Western blot analysis confirmed the increase of 14-3-3 zeta, pRKIP and prohibitin
protein levels in PrEC cells co-cultured with patient EVs. 14-3-3 proteins were also found as common proteins of
3 other Gleason grade 8 patients.
Conclusion: Our study provides a rational basis to further investigate putative proteins, such as 14-3-3 and
prohibitin and genetic factors that may be responsible for phenotypic changes that are associated with prostate
cancer progression.
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Gene ontologyIntroduction
Prostate cancer is the most frequently diagnosed malig-
nancy and ranks second amongst all cancers in men
with an estimated 218,890 men in the United States
every year and 27,350 deaths per year (American Cancer
Society 2007). Patients enjoy a 5-year survival rate ap-
proaching nearly 100%. However, as evidence of the slow
but steady nature of this disease, 30-40% of patients will* Correspondence: devasis_chatterjee@brown.edu
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distribution, and reproduction in any mediumexperience a PSA recurrence within 10 years following
definitive surgery or radiation therapy [1]. Patients with
high risk or advanced disease or staging, or who have
suffered a recurrence, historically receive treatment with
androgen ablation therapy. Sometimes these failures are
supplemented with salvage radiation therapy and pos-
sibly receive chemotherapy [2-5]. The progression of dis-
ease is inevitable and as a result, the median survival in
advanced disease is only 18 to 20 months with an overall
survival of 24 to 36 months. Therefore, there is an ur-
gent need to identify novel genes or proteins that may
be useful in selecting patients for mechanism-based
therapeutics to improve clinical outcome.Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tifying soluble factors secreted by tumor cells and char-
acterizing their paracrine activities [6-10]. In addition to
soluble paracrine factors, many tumor cells also release
extracellular vesicles (EVs), microvesicles (MVs) or
exosomes. These vesicles are distinguished by their size
(30–1000 nm) and morphology and are secreted by a
variety of cell types under physiological and pathological
conditions; specifically they are secreted when a
multivesicular endosome fuses with the plasma mem-
brane [11,12]. According to previous studies, EVs can
contain bioactive molecules, nucleic acids, and/or pro-
teins [13]. Interestingly, the abundance of EVs released
generally correlates positively with advanced grade and
stage of cancer progression [14]. Activated cells of vari-
ous types are known to produce and shed membrane
EVs into their surroundings. However, the mechanism
triggering EV generation by cancer cells is unknown.
There is mounting evidence that vesicle trafficking is a
highly important process in tumorigenesis. Further
evaluation of vesicle trafficking may reveal a number of
targets and strategies that may be important for cancer
therapeutics.
Previously, it has been shown that various aspects of
cellular phenotype can be transferred from one cell type
to another via EVs. Accordingly there has been a strong
focus on the use of EVs as a vaccine in cancer [15]. This
includes the transfer of cell surface molecules of mRNA
and of apoptotic bodies. One study investigated the se-
cretion of EVs from the human prostate cancer cell lines,
DU145 and LNCaP, and showed an association with a
region of frequent chromosomal deletion in metastatic
disease [16]. This work suggested that EVs shed from
prostate cancer cells could alter the tumor microenvir-
onment in a manner that may promote disease progres-
sion. A recent publication has demonstrated that
proteins found in PC-3 cell released EVs that are mainly
involved in transport, cell organization and biogenesis,
metabolic process, response to stimulus, and regulation
of biological processes [17].
In this study we confirmed that EVs could be utilized
as a potential mechanism of suppressing growth and re-
versing the cancerous phenotype. We demonstrate that
we can reverse the resistance of prostate cancer cells to
CPT via EVs as measured by apoptosis, cytotoxicity, and
growth in soft agar. In addition, growth in soft agar, a
hallmark of malignant cells, can be inhibited when
DU145 cells are co-cultured with EVs isolated from non-
malignant human prostate epithelial (PrEC) cells with
the reciprocal result occurring with PrEC cells co-
cultured with DU145 EVs. Phosphoproteomic analysis
revealed the transfer of numerous proteins in our co-
culture model. Two proteins of significance, Suppressor
of cytokine signaling 3 (SOC3) and Signal transducerand activator of transcription 3 (STAT3) were acquired
or inhibited by co-culture of PrEC EVs with DU145 cells.
Similarly, we found the increase in 14-3-3 zeta/delta
phosphorylated Raf kinase inhibitor protein (pRKIP) and
prohibitin from EVs isolated from 2 patient samples and
co-cultured with PrEC. 14-3-3 zeta/delta/eta was also
found as a common protein from 3 other Gleason grade
8 patients. The link between these proteins with cell sur-
vival, apoptosis induction, and tumor promotion provide
a rational basis for therapeutic intervention. Therefore
our study provides the basis for examining proteins re-
leased by EVs that are associated with disease progres-
sion and phenotype switching.
Materials and methods
Materials All reagents and chemicals were purchased
from Sigma Chemical Co. (St. Louis, MO) unless other-
wise noted. ST2461, a CPT analog, was provided by Sigma
Tau (Rome, Italy). Protein quantification reagents were
obtained from Bio-Rad Laboratories, Inc. (Hercules, CA).
Enhanced chemiluminescence reagents and secondary
mouse and rabbit horseradish peroxidase-conjugated anti-
bodies for Western blot analysis were ordered from GE
Healthcare (Arlington Heights, IL). The antibody to RKIP
was purchased from Millipore (Hopkington, MA); the
actin-HRP, pRKIP, SOCS3, prohibitin, 14-3-3 zeta and
STAT3 antibodies were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA); and the PARP antibody was
purchased from Invitrogen (Carlsbad, CA).
Cells
The human prostate carcinoma cell line DU145 was pur-
chased from ATCC (Rockville, MD). The RC1 cell line,
which was derived from DU145 cells, has been described
[18]. The cell lines in our lab were used between passage
numbers 10–20. The cells were grown in RPMI 1640
medium and supplemented with 10% fetal calf serum,
glutamine, non-essential amino acids, 100 units/ml peni-
cillin and 50 units/ml streptomycin and cultured in a hu-
midified incubator at 37°C containing 5% CO2. The PrECs
utilized in this study were obtained from Dr. William Hahn
at Dana Farber Cancer Institute, Boston, MA [19] and were
gown in PrEBM media supplemented with PrEGM
SingleQuots (Lonza, Walkersville, MD). PrECs were used
in between passage 2 and 10.
Western blot analysis
Total cell extracts were prepared as previously described
[18]. Protein concentrations of lysates were determined
using the Bradford assay kit (BioRad). Proteins were sepa-
rated by SDS-PAGE and electrophoretically transferred
from the gel to nitrocellulose membranes (GE Healthcare).
Proteins recognized by the antibodies were detected by
enhanced chemilluminescence reagents (GE Healthcare).
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Consent was obtained according to the Rhode Island
Hospital’s Committee on Protection of Human Subjects
(Institutional Review Board) for each of the patients in-
volved. In collaboration with our colleagues, we obtained
fresh prostate tissue specimens following robotic assisted
laparoscopic prostatectomy (Da Vinci Robotic Surgical
System at The Miriam Hospital). In accordance with the
requirements mandated by the Department of Health
the active robotic surgeons have maintained a detailed
database with preoperative, intraoperative and postoper-
ative parameters recorded for each case. We isolated
EVs from two patients; Patient 18: Gleason 4 + 4 = 8 with
tertiary 5 pattern (high risk) prostate cancer with posi-
tive margin focally and seminal vesicle invasion (path-
ology stage T3b). Patient 19: Gleason 4 + 4 = 8 with
tertiary 5 pattern (high risk) prostate cancer with nega-
tive margins (pathology stage T3a). Patients 13, 14, and
16 were also Gleason grade 8.
Extracellular vesicle isolation
Extracellular vesicle isolation was conducted for five dif-
ferent patient cancer tissue samples with Institutional
Review Board approval at Rhode Island Hospital. Tumor
samples were weighed and minced with a sterile scalpel
into 1-2 cm pieced as previously reported [20]. Tissue
pieces were then subjected to enzymatic dissociation
using 0.2% collagenase in DMEM with 10% FBS for
90 minutes at 37°C and passed sequentially through 18,
22, and 25 gauge needles followed by a 40 um cell
strainer as reported. The cell suspension was washed
twice with DMEM and plated into a T-75 tissue culture
flask with growth media consisting of DMEM 10% EV-
free FBS, 1% penicillin-streptomycin. EVs were also iso-
lated from DU145 and PrEC cell lines. DU-145 cells
were plated at 1.5 × 105 cells per T75 flask, and PrECs
were plated at 1.5 × 106 cells per 100 mm plate. Cell cul-
tures were maintained under the previously listed condi-
tions, and after 7 days of culture, or approximately 5
doublings of normal and tumor tissue as previously
reported, the medium from the cultured cells was re-
moved and further processed to isolate EVs [20].
The medium for EV isolation was centrifuged at 300 ×
gravity for 10 minutes at 4°C. The supernatant was UCF
(ultra-centrifuged) at 24,000 × g for 1 hour at 4°C. The UCF
pellet was resuspended in growth medium and co-cultured
(self-culture or cross-culture) with cells for 4–7 days. The
UCF pellet was further processed for co-culture (see below)
or the isolation of protein for phospho-protein (Kinexus)
and Mass Spec analysis. The supernatant from EV isolation
was used as conditioned medium (CM) and was concen-
trated using Amicon Ultra-15 centrifugal filter unit
(Millipore, Billerica, MA). The CM was filter sterilized and
used for co-culture experiments described below.Co-culture of prostate tissue extracellular vesicles with
non- and malignant prostate epithelial cell lines
Non-malignant human PrECs and malignant DU145 prostate
cells were grown in Lonza Bullet or RPMI medium, respect-
ively supplemented with special additives (PrEC) or 10%
dialyzed EV-free FBS and antibiotics (DU145). The cells were
co-cultured with EVs, from normal or malignant prostate
tissue. Specifically, PrECs were co-cultured with EVs from
prostate tumor tissue and malignant DU145 cells with EVs
derived from normal prostate tissue. PrEC cells were also
co-cultured for 7 days with CM isolated from DU145 cells.
Soft agar cloning
Following EV co-culture, cells were grown in normal
growth medium. After 7 days, cells were harvested for
soft agar colony formation. The lower layer of the dish
contained 2 ml of 1% agarose mixed with growth media;
on the top level, 0.4% agarose mixed with growth media
and 0.05 – 1 × 105 cells to a final volume of 1 ml. Plates
were incubated in 5% CO2 at 37°C for 2–3 weeks. Col-
onies were then counted and images were captured on a
Olympus MT2 microscope. Each experiment was ana-
lyzed in quadruplicate by 3 different individuals.
Kinex™ antibody microarray analysis
The Kinex™ antibody microarrays are printed in quadrupli-
cate in 32 grids of 8 × 12 spots each on glass microscope
slide-sized chips with 854 antibodies from over 20 different
commercial suppliers. They include 517 pan-specific anti-
bodies for measurement of expressions of 309 protein ki-
nases and 218 other signaling proteins, as well as 337
phospho-site-specific antibodies [21,22]. To perform a
Kinex™ analysis, extracellular vesicles were harvested as
previously discussed and co-culturing was conducted with
1 × 106 cells on 100 mm plates. Cells were harvested
washed twice with PBS, and centrifuged at 14,000 × g for
5 minutes. Supernatant was discarded and the resulting
pellet was frozen at −20°C. The lysates with 50 ug protein
each from the samples were labeled with the same propri-
etary fluorescent dye. Each sample was separately applied
to opposite sides of the antibody microarray that contains
a dam to prevent mixing of the samples. Following incuba-
tion of the samples with the Kinex™ chip, the unbound
proteins were washed away and the chips were scanned
with a Perkin-Elmer Scan Array Express Reader. Image
analysis of the TIF files that were produced was performed
with ImaGene 7.0 software from BioDiscovery (El Segundo,
CA). Quantification of the signal intensity of all of the
detected spots revealed that the difference between dupli-
cates was within 10% for half of all of the antibodies used.
Protein extraction for Mass Spectrometry analysis
Protein lysates from PrECs that were co-cultured with
patient EVs for 7 days and control PrECs co-cultured
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quential Extraction Kit (Bio-Rad) and then the sequen-
tial extractions were combined and cleaned up using a
ReadyPrep 2-D Clean-Up Kit (Bio-Rad). Total protein
concentration was determined using a BCA protein
assay kit (Thermo Scientific). Samples were then re-
solved using NuPAGE SDS-PAGE system (Invitrogen)
(4-12% acrylamide, Bis-Tris with MES SDS Running Buf-
fer) and stained with Gel Code Blue Stain (Thermo Sci-
entific). Gel lanes corresponding to each sample were
excised into 3 bands that covered regions of high,
medium, and low molecular weight proteins to reduce
sample complexity. Each band was then cut into 6 mm
wide pieces and subjected to in-gel tryptic digestion, and
then each fraction was washed/dehydrated twice in a 1:1
solution of 0.1 M ammonium bicarbonate (Sigma) and
100% ACN (Sigma). Disulfide bonds were reduced with
10 mM dithiothreitol (DTT)(Thermo)/0.1 M ammonium
bicarbonate for 45 min at 56°C and alkylated with
55 mM iodoacetamide (IAA)(Sigma) for 30 min at room
temperature in the dark, and washed/dehydrated twice
as explained above followed by trypsin digestion over-
night at 37°C. After trypsin digestion, peptides were
extracted using 25 mM ammonium bicarbonate and
100% ACN, followed by two rounds of 5% formic acid
and 100% ACN. The extracts were pooled, dried in a
vacuum centrifuge, and stored at −20°C until LC/MS
analysis.
Liquid chromatography/ MS analysis of protein digests
Mass spectrometry analysis was performed at the Rhode
Island Hospital Proteomics Core facility by nano-LC-
ESI-MS/MS using an Ultimate3000 nano-LC system
(Dionex) controlled with Chromeleon software coupled
to a QSTAR XL (Applied Biosystems, Concord, Ontario,
CA) mass spectrometer. Tryptic digests were fraction-
ated by reversed-phase chromatography using a C-18
PepMap 100 column (75 μm id × 15 mm, 3 μm particle
size, LC Packings/Dionex, Sunnyvale, CA) operating at a
flow of 300 nL/min. A linear separation gradient applied
was starting at 5% (v/v) ACN in 0.1% (v/v) formic acid
(Buffer A) to 95% (v/v) ACN in 0.1% (v/v) formic acid
(Buffer B) over a 40 min gradient. The column eluate was
introduced directly into the mass spectrometer via ESI.
Candidate ions were selected and fragmented using a
standard information dependent acquisition (IDA)
method. One second MS scans (range between 350 and
1800 Thompson, Thompson (Th) = Da/z) were used to
identify candidates for fragmentation during MS/MS
scans. MS/MS scans (2 s; range between 150 and 1800
Th) were collected up to three times after each survey
scan. In order for an ion to be considered a candidate
for fragmentation it had to be assigned a charge in the
range of +2 to +4.Data processing for protein identification and quantitation
Raw LC-MS/MS data were converted using ABSciex MS
Data converter software (v1.3 beta) to mgf format for
protein identification using MASCOT v2.3.2 search en-
gine (Matrix Science, Boston, MA, USA) by searching
against a non-redundant human UniProt database (April
20th, 2012, containing 87,656 protein entries) using the
following parameters: tryptic peptides with up to two
missed cleavage sites, peptide tolerance of 0.2 Da, frag-
ment tolerance of 0.5 Da, instrument type: ESI-QUAD-
TOF, and variable modifications: methionine oxidation.
For label-free protein quantitation and proteome com-
parisons, raw files were converted to mzXML format
using ABSciex MS Data converter software (v1.3 beta)
and uploaded along with Mascot search results in .dat
format into ProteoIQ software (v.2.3.08 BIOINQUIRE
Athens, GA, USA). Spectral counting and relative inten-
sity quantification were performed using precursor ion
intensities, with the following parameters: mass toler-
ance of 20 ppm, minimum peptide length of 6 amino
acids, protein probability of 0.5, and peptide probability
of 0.05. After protein set generation, the proteins were
further filtered using a 0.9 protein probability and nor-
malized according to the number of spectra in each
sample. Then the proteins which the 5 Gleason grade 8
patients had in common were placed in a new protein
set and were filtered using GO annotations which de-
scribe the role of a given gene in a biological process, its
molecular function, and cellular component. The GO
terms which were selected to filter the results are related
to apoptosis, inflammation, immune response, DNA
transcription, and DNA translation in order to deter-
mine the importance and behavior of these proteins in
apoptotic and cell survival pathways.
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems,
Redwood City, CA, USA) was used to identify protein net-
works according to biological functions and/or diseases in
the Ingenuity Pathway Knowledge Base (IPKB). The protein
accession numbers and the corresponding log2 relative ex-
pression values were uploaded into IPA, where the log2
relative expression values are converted to fold change
values by the software. Then using these fold change values
(with a cutoff of 1.5 for up- or down- regulation) for each
protein, IPA determines the statistically relevant (p < 0.05)
canonical pathways and functions related to the proteins in
each sample. Each pathway and function is assigned a –log
(p-value) that is determined by the number of proteins
present in the specific pathway or function and the statis-
tical significance of the expression level of the protein.
Statistical methods
All cell culture experiments were repeated at least 3
times, unless indicated otherwise, and paired t-tests were
used to determine statistical significance.
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Extracellular vesicle-mediated reversal of drug resistance
in prostate cancer
Chemotherapy is currently the major treatment option for
castration-resistance prostate cancer. However, chemore-
sistance is inherent in half of all patients that receive
chemotherapy, and the decline of sensitivity to therapeutic
agents in patients that initially respond is inevitable [23].
Multiple cellular pathways involving apoptosis, inflamma-
tion, angiogenesis, signaling intermediaries, drug efflux
pumps, and tubulin are implicated in the development of
chemoresistance [23]. It has been shown that resistance to
CPT in DU145 cells is due, in part, to expression of Raf
kinase inhibitor protein (RKIP) [18]. We hypothesized that
in addition to RKIP, resistance to CPT may be due to the
release of EVs.
To investigate the effects of EV-mediated transfer of
chemoresistance in prostate cancer, we studied the mech-
anism of resistance to camptothecin (CPT) in human
prostate cancer cell lines. The DU145 cell line, a human
prostate carcinoma cell line, undergoes extensive apop-
tosis when treated with 9-nitrocamptothecin (9NC) [18].Figure 1 Extracellular vesicle-mediated reversal of apoptosis resistanc
The EVs were resuspended in PBS. DU145 cells were co-cultured with RC1
EV and EV co-cultured cells were treated with 100 nM CPT for 24 h and ex
(unless indicated 50 μg/sample was used for Western blot analysis) were se
with antibodies to the indicated proteins. C,D. The same experiment from
propidium iodide staining using a flow cytometer. The data is the mean +/
all Western blots described in this Figure legend and for all other subsequent F
was variable.CPT inhibits topoisomerase I, thereby inducing single-
strand breaks into the DNA molecule [24]. Conditioned
media from parental DU145 cells and DU145 cells resist-
ant to CPT (RC1 cells) were collected, ultracentrifuged,
and EVs were collected for co-culture [20]. EVs isolated
from DU145 cells were co-cultured with RC1 cells and
EVs from RC1 cells were co-cultured with DU145 cells.
After 6 days, both groups were treated with CPT, cells
were harvested and analyzed for apoptosis via Poly ADP
Ribose Polymerase (PARP) cleavage. Upon DNA damage
PARP signals DNA repair enzymes. Treatment of DU145
with CPT indicates an increase in PARP cleavage com-
pared to untreated control cells (CTR) indicating PARP
mediated activation of DNA repair while DU145 cells co-
cultured with EVs derived from RC1 cells demonstrated re-
duction in PARP cleavage similar to the control (Figure 1A,
B). These results demonstrate EV-mediated chemoresis-
tance of DU145 cells. DU145 cells co-cultured with RC1
EVs did not undergo apoptosis after CPT treatment,
whereas the RC1 cells co-cultured with the DU145 EVs
were now sensitized to the apoptosis-inducing effects of
CPT (Figure 1C, D). The same experiment was repeatede and sensitivity. A, B. EVs were isolated from DU145 and RC1 cells.
EVs (REV) and RC1 cells were co-cultured with DU145 EVs (DEV). Non-
amined for PARP cleavage and actin via Western blot analysis. Proteins
parated by 10% SDS-PAGE, transferred to nitrocellulose and analyzed
B,C was repeated and the samples were examined for apoptosis via
− s.d. of 2 independent experiments performed in triplicate. Note: for
igure legends, the exposure time used to identify the various proteins
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As noted in Figure 1C, DU145 cells became resistant to
CPT-induced apoptosis after co-culture with RC1 EVs.
Conversely, RC1 cells underwent apoptosis after being co-
cultured with DU145 cells EVs and then treated with CPT
(Figure 1D). These results indicate a phenotypic shift facili-
tated by the co-culturing with EVs.
Extracellular vesicle-mediated reversal of malignant
prostate cancer phenotype
To better understand the phenotypic switching capacity of
EVs, several strategies were applied. One of the hallmarks
of malignant transformation of cells is the ability to exhibit
anchorage-independent growth [25]. Therefore, we contin-
ued to examine EV-mediated phenotype changes using a
non-malignant model of prostate cancer in a malignant cell
line to see if the phenotype can be transferred as measured
by soft agar colony formation. EVs were harvested from a
malignant human prostate cancer cell line (DU145), as well
as from an immortalized, non-tumorigenic prostate epithe-
lial cell line (PrEC cells), and were collected for co-culture
for vesicle characterization. EVs isolated from DU145 cells
were co-cultured with PrECs and EVs from PrEC cells
were co-cultured with DU145 cells. The number of EVs
used for co-culture was normalized by counting the total
number of EVs within a particular size of 30-1000 nm
using the NanoSight NS500 (NanoSight, Wiltshire United
Kingdom).
After 7 days in culture, we measured the ability of
each experimental condition (from above) to display an-
chorage independent growth in soft agar for 14 days.
Since the malignant phenotype includes an increased
ability to exhibit anchorage-independent growth, a sig-
nificant increase or reduction in the number of colonies
generated was viewed as a shift towards a tumorigenic
phenotype or towards a normal phenotype, respectively.
As shown in Figure 2, co-culture of DU145 cells with
EVs isolated from PrECs prevented the colony formation
in soft agar, indicating that anchorage-independent
growth was significantly suppressed (p < 0.0004) in com-
parison to DU145 cells without EVs (Figure 2A). Re-
markably, the reciprocal effect was also observed where
significant changes in colony formation and anchorage
independent growth in non-tumorigenic PrECs that
were co-cultured with EVs isolated from DU145 cells
(p < 0.0003) compared to PrECs without EVs (Figure 2A).
To determine if the results we observed were a direct ef-
fect of EV co-culture with recipient cells or could be re-
capitulated indirectly with factors (i.e., cytokines, growth
factors, etc.) released into the medium, we isolated CM
from DU145 cells used for EV purification. As shown in
Figure 2B, EVs isolated from DU145 cells stimulated
PrEC soft agar colony formation. In contrast, CM iso-
lated from DU145 cells did not significantly changePrEC soft agar growth (Figure 2B). This indicates that
the phenotype shift we observed is a direct effect of
DU145 EVs.
Kinexus proteomic antibody array analysis of transferred
proteins
To determine the proteins that are involved in or might
be responsible for “phenotypic switching”, we utilized
Kinexus phospho-protein microarray analysis (Vancouver,
BC) in the DU145 cells co-cultured with PrEC EVs.
EVs were isolated from PrECs after 7 days in culture as
described [20]. PrEC EVs were then co-cultured with
DU145 cells for 7 days after which the cells were
harvested and the pellet sent to Kinexus Bioinformatics
for analysis. The ability of EVs to elicit a phenotypic
switch was therefore verified in the proteins that were
transferred and analyzed. As a control a sample with
DU145 cells co-cultured with DU145 EVs was also gen-
erated. Table 1 shows a portion of the results of the
microarray analysis indicating the fold change in protein
expression (Z score ratio).
To further validate these results, we confirmed the
proteomic data with Western blot analysis. We
performed Western blot analysis with an aliquot of the
sample that was retained in the lab prior to the shipment
of the samples to Kinexus. We observed a reduction
STAT3 expression in DU145 cells co-cultured with self-
EVs, in comparison to DU145 cells co-cultured with
PrEC EVs. Further, there was a significant increase in
SOCS3 expression in the DU145 cells co-cultured with
PrEC EVs (Figure 3). It should be noted that we did not
observe any difference in the levels of the proteins ex-
amined in parental DU145 cells when compared to
DU145 cells co-cultured with DU145 EVs (data not
shown). Our results implies that aberrant STAT3 signal-
ing may be inhibited by EV release and transfer of
SOCS3 or regulators of STAT3 signaling network.
Mass spectrometry analysis of prostate cancer patient
derived extracellular vesicles
We extended our studies on DU145 and PrEC EVs and
phenotype shifting to EVs derived from 2 prostate cancer
patients both with Gleason grade 8. Soft agar growth
was measured in PrECs after co-culture with EVs from
prostate cancer patients 18 and 19. EVs from patients 18
or 19 significantly increased soft agar growth in non-
malignant PrECs (p < 0.0005 and p < 0.0001, respectively)
(Figure 4). A portion of the sample used for soft agar
cloning was analyzed by mass spectrometry. Table 2
shows a partial list of the proteins identified in PrECs
exposed to tumor-derived EVs from patients 18 and 19
as well as the log2 relative expression of each protein.
Some 14-3-3 isoforms are associated with increased ma-
lignancy and are therapeutic targets [26] and our
Figure 2 Extracellular vesicle-mediated reversal of soft agar growth. A, EVs were isolated from normal prostate (PrEC) and malignant
(DU145) cells. PrECs were co-cultured with DU145 EVs and DU145 cells were co-cultured with PrEC EVs for 7 days. B, The same experiment from
A was repeated with EVs and conditioned medium (CM) isolated from DU145 cells and co-cultured with PrEC cells for 7 days. 50 mls of CM was
concentrated and used for the experiment. In both experiments, cells were harvested and utilized for soft agar cloning. Soft agar cloning was
examined using 0.7% agarose in PBS and mixed with 1× media with 10% FBS. The top layer consisted of 0.35% agarose in PBS, 1× media with
10% FBS, and 1 x 105 cells per dish. Dishes were incubated at 37°C and 5% CO2. After two weeks, cell colonies were counted. 5 fields/dish
using the 40× objective were counted and there were 5 dishes/condition. A paired t-test was performed to analyze the increase in soft agar
colony formation of in A: PrEC + DU145 EVs when compared to untreated PrEC cells, * p < 0.002, and the decrease in soft agar colony formation
of DU 145 + PrEC EVs when compared to untreated DU145 cells **p < 0.0004. In B: PrEC + p < 0.0003 when compared to untreated PrEC
cells. *p < 0.0005.
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was confirmed by Western blot analysis (Figure 4). Also
of note is the increase in pRKIP when patient 18 and 19
EVs were co-cultured with PrECs in reference to the
levels of RKIP in PrECs alone. RKIP has been shown to
regulate apoptosis and cell survival in prostate cancer
[18]. Western blot analysis revealed that RKIP was phos-
phorylated after co-culture of patient 18 and 19 EVs with
PrECs (Figure 5A). This result would explain, in part,
our data in Figure 4 because pRKIP antagonizes the
function of RKIP and allows for Raf/MAPK signaling to
occur. This pathway promotes oncogenesis and cell pro-
liferation and, presumably, soft agar growth.In our analysis of the total proteome content of PrECs
exposed to EVs derived from patient 18, we identified 36
protein groups in PrECs alone and 44 protein groups in
PrECs with Patient 18 EVs. From these, 8 protein groups
were unique to PrECs and 16 were unique in Patient 18
EVs with 28 common protein groups (Figure 5B). Expos-
ure of PrECs with EVs from Patient 19 yielded similar
results (Figure 5C). For example, Macrophage migration
inhibitory factor (Uniprot ID: MIF_HUMAN) and
Peptidyl-prolyl cis-trans isomerase A (Uniprot ID:
PPIA_HUMAN) were found to be unique in both Pa-
tient 18 EVs and Patient 19 EVs when compared to
PrECs alone. Analysis of proteome content between
Figure 3 Extracellular vesicle-mediated changes in cellular
protein expression. EVs were isolated from DU145 and PrECs and
resuspended in PBS. EVs were co-cultured with DU145 cells and
whole cell lysates were prepared for Western blot analysis as
reported. Western blot analysis results show that DU145 cells
co-cultured with self-EVs have enhanced expression of STAT3, while
co-culture with PrEC EVs leads to increased expression of SOCS3.
Table 1 EV-mediated transfer of proteins via Kinexus
phospho-protein microarray analysis in DU145 cells
co-cultured with PrEC EVs


















Extracellular vesicles were isolated from PrECs after 7 days in culture as
described. PrEC EVs were then co-cultured with DU145 cells for 7 days after
which cells were harvested and the harvested cell pellet sent to Kinexus
Corporation, Vancouver, BC for analysis. As a control, a sample with DU145
cells co-cultured with DU145 EVs was also generated. These are a portion the
results of the array analysis indicating the fold change in protein expression
(Z score) of DU145 cells co-cultured with PrEC EVs when compared to DU145
cells co-cultured with DU145 EVs.
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the numbers of protein groups identified in each sample
indicating low patient heterogeneity (Figure 5D).
We examined the EV content of 3 additional Gleason
grade 8 patients (Patients 13, 14, and 16) (Figure 6). The
Venn diagram shows that there are 222 common pro-
teins between these patients. The bar graph shows the
functionalities listed by IPA based on the ProteoIQ pro-
tein relative expression values. The relative expression
value of each protein in addition to the presence or ab-
sence of key proteins associated with that term both
contribute to the significance value assigned to each
function or pathway (indicated by the threshold line
across the bar graph in Figure 6). The terms presented
in the bar graphs were selected because they are related
to cancer and/or are important topics discussed in the
paper.
In addition, we compared patients 18 and 19, with pa-
tients 13, 14, and 16, and determined the common pro-
teins between these 5 Gleason grade 8 patients. These
71 common proteins between the 5 Gleason grade 8 pa-
tients were then further filtered according to GO anno-
tations which are related to apoptotic and cell survivalpathways (seen in Tables 3, 4, 5, and 6). Some of the
common proteins included: Prohibitin (Uniprot ID:
PHB_HUMAN), 14-3-3 (Uniprot ID: 1433E_HUMAN) ,
and Annexin A1 (Uniprot ID: ANXA1_HUMAN). The
importance of the proteins found in these tables is that
we found proteins across all patients that are associated
with apoptosis, growth and proliferation, inflammation,
immune response, and DNA transcription and transla-
tion. Again with all 5 Gleason grade 8 patients was
detected that 14-3-3 zeta/delta/eta was a protein in com-
mon with all 5 patients (Table 2 and Additional file 1:
Table S1). This proves that there is level of homogeneity
in protein content amongst these 5 Gleason 8 patients,
which provides a basis for targeting these proteins to im-
prove therapeutic methods.
We also analyzed this group of 71 proteins using IPA
to determine whether the interaction of these proteins is
similar across all of the patients. IPA showed that there
is similarity in the level of significance of functions and
Figure 4 Enhancement of soft agar growth via prostate patient-derived EVs. EVs were isolated from 2 prostate cancer patients with
Gleasons grade 8. The EVs were co-cultured with PrECs for 7 days after which soft agar growth was determined. 6 fields/dish were counted and
the data represents the mean +/− s.d. of 2 independent experiments performed in triplicate. A paired t-test was performed to analyze the
increase in soft agar colony formation of PrEC cells when co-cultured with EVs from patient 18, * p < 0.0005, and patient 19 **p < 0.0001 when
compared to untreated PrEC cells. Note the increase in colony size in PrECs (bottom panel) co-cultured patient tumor EVs. The pictures are
representative of an area of a field that was counted.
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across all the patients. The data sets from the 5 patients
were compared using a Comparison Analysis Tool in the
IPA software. The p-value, in this case, is the measure of
the likelihood that the association between a set of genes
in the dataset and a related function or pathway is due
to random association. The cutoff value for the bar
graph is set at p < 0.05 (or –log < 1.3) as indicated by the
threshold line in Figure 7. So all the functions across all
the patients show a statistically significant non-random
association, and the majority of the pathways across all
the patients also show a statistically significant non-
random association. The fact that some of the canonicalTable 2 Comparison of relative protein expression between P
Accession # Protein name PrEC vs. PrEC + P18 EV
Log2 # Pep
P62258 14-3-3 protein zeta −0.64 2
P06733 Alpha-enolase 0.051 5
P04083 Annexin A1 0.47 9
P00403 Cytochrome c oxidase subunit 2 0.86 4
P68104 Elongation factor 1-alpha 1 0.04 8
P30086 PEBP1 (RKIP) 1.12 5
P35232 Prohibitin 0.08 2pathways are statistically significant in some patients but
not in others can be attributed to some level of hetero-
geneity across patients. But for the majority of the func-
tions and canonical pathways, the level of homogeneity
in protein content and function and pathway signifi-
cance can clearly be seen and can definitely prove to be
a useful tool in the future development of targeted can-
cer therapeutics.
Discussion
The results of this study provide direct evidence of the
therapeutic potential of EVs in prostate cancer. The
phenotypic changes derived by EV co-culture withrECs alone and PrECs co-cultured with patient EVs
s PrEC vs. PrEC + P19 EVs PrEC + P18 EVs vs. PrEC + P19 EVs
Log2 # Pep Log2 # Pep
0.59 2 1.23 2
0.044 2 −0.007 2
0.69 10 0.22 10
0.82 4 −0.04 4
0.39 8 0.35 8
1.88 4 0.75 4
0.41 2 0.33 2
Figure 5 Detection of proteins from patients EVs. A. EVs were isolated from conditioned medium from tissue biopsied from 2 patients as
described in Experimental procedures. EVs were co-cultured with PrECs for 7 days. A portion of the sample was used for mass spec analysis while
the other for Western blot analysis. We examined the expression of pRKIP, RKIP, 14-3-3 zeta and actin based on the Uniprot ID data (Table 2). B.
Venn diagram comparing the protein content of PrECs alone vs. PrECs co-cultured with Patient 18 EVs (8 proteins were unique to PrECs alone, 16
proteins were unique to PrECs co-cultured with Patient 18 EVs, and 28 proteins were found in common). C. Venn diagram comparing the protein
content of PrECs alone vs. PrECs co-cultured with Patient 19 EVs (8 proteins were unique to PrECs alone, 15 proteins were unique to PrECs
co-cultured with Patient 19 EVs, and 28 proteins were found in common). D. Venn diagram comparing the protein content of PrECs co-cultured
with Patient 18 EVs vs. PrECs co-cultured with Patient 19 EVs (44 proteins were unique to PrECs co-cultured with Patient 18 EVs, 43 proteins were
unique to PrECs co-cultured with Patient 19 EVs, and 38 proteins were found in common).
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tential of EVs in the horizontal transfer of proteins. This
can provide a potential opportunity for the development
of new diagnostic and/or therapeutic measures. By ma-
nipulating the uptake, incorporation, and expression of
exogenous material from EVs may results in phenotype
switching. Horizontal gene transfer is understood to in-
clude any mechanism where genetic material is ex-
changed from non-parent donors to recipient cells.
These methods include cell-cell interactions, such as cell
fusion, and cellular interactions with mobile genetic ele-
ments, including plasmids and bacteriophages [27].
Other methods of horizontal gene transfer have been
implemented in the studies of tumor progression. Gaiffe
et al. illustrated that apoptotic cells can serve as DNA
vectors through an endocytic process where apoptotic
cells are internalized by non-specialized cells [28]. As
successful gene transfer depends on in situ signaling,
recognition, molecular triggers, and the surrounding en-
vironment, it is surprising that such unlikely elements
can drive phenotype-switching, and consequently tumor
progression.
In this manuscript we show that the phenotypes asso-
ciated with malignant transformation and normal cell
growth in prostate cells, as well as chemo-resistance/-sensitivity, can be transferred by EVs and via biopsied
EVs isolated from patient tumor cells. Seemingly, expos-
ing cells of a normal prostate phenotype with EVs from
a malignant phenotype, and vice versa, leads to a trans-
fer of biological materials between phenotypes, and
therefore triggers genetic changes within the cells. Our
results demonstrate that the cancer phenotype in pros-
tate cells can be reversed or transferred via EVs. The
transfer of genetic material derived from non-malignant
prostate cells via EVs to a malignant cell line in vitro
seemingly reversed the malignant transformation of the
prostate cells. One unanswered question is whether the
reciprocal events are occurring; if malignant-derived EVs
transferred to normal cells fully facilitate a change to
malignant phenotype, or if they are limited to promotion
of specific hallmarks of malignant transformation. Al-
though EVs from explant tissues (patient tissue samples)
significantly increased soft agar growth in normal PrECs
and malignant DU145 prostate cells, demonstrating an
EV-mediated promotion of the malignant phenotype,
our results are insufficient to conclude that this promo-
tion would lead to tumorigenesis in vivo.
Notably, the observed genetic changes resulting from
the EV-mediated, horizontal gene transfer included alter-
ations in the expression of several clinically relevant
Figure 6 Common proteins between patients 13, 14, and 16 and associated functions and canonical pathways. The Venn diagram shows
the common and unique proteins between patients 13, 14, and 16, A The bar graphs show the significance (−log(p-value)) of specific functions,
B, and canonical pathways, C, in each patient. The threshold cutoff of significance is p < 0.05 (or –log = 1.3).
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correlation between the expression levels of RKIP and
tumorigenicity in prostate cancer cells [18]. RKIP isrequired for human cancer cells to undergo drug-
induced apoptosis, and it suppresses metastasis in pros-
tate cancer. In regard to chemosensitivity, Chatterjee
Table 3 Apoptosis related proteins found in the common
proteins between patients 13, 14, 16, 18, and 19
Accession # Protein name
P62258 14-3-3 protein epsilon
P63104 14-3-3 protein zeta/delta
P10809 60 kDa heat shock protein, mitochondrial










P14618 Pyruvate kinase isozymes M1/M2
P08670 Vimentin
P21796 Voltage-dependent anion-selective channel protein 1
P13010 X-ray repair cross-complementing protein 5
Using Gene Ontology (GO) terms, the common proteins between patients 13,
14, 16, 18, and 19 were filtered according to GO terms which are related
to apoptosis.
Table 5 Growth and proliferation related proteins found
in the common proteins between patients 13, 14, 16, 18,
and 19
Accession # Protein name
P62258 14-3-3 protein epsilon
Q04917 14-3-3 protein eta
P11021 78 kDa glucose-regulated protein
P04083 Annexin A1
P07355 Annexin A2
P06576 ATP synthase subunit beta, mitochondrial
P27797 Calreticulin
Q00610 Clathrin heavy chain 1
Q06830 Peroxiredoxin-1
P35232 Prohibitin
P13010 X-ray repair cross-complementing protein 5
Using Gene Ontology (GO) terms, the common proteins between patients 13,
14, 16, 18, and 19 were filtered according to GO terms which are related to
the growth and proliferation of cells.
Table 6 DNA transcription and translation related proteins
found in the common proteins between patients 13, 14,
16, 18, and 19
Accession # Protein name
Q04917 14-3-3 protein zeta
P63104 14-3-3 protein zeta/delta
P06733 Alpha-enolase
P27824 Calnexin
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apoptosis during chemotherapy treatment in drug-
sensitive human prostate cells, but does not in drug-
resistant cells [18]. Maximal cellular expression levels of
RKIP correlated perfectly with the onset of apoptosis in
chemosensitive cells, but in cells that were resistant to
DNA-damaging agents, treatment with such drugs did
not up-regulate RKIP expression.
We confirmed that RKIP plays a similar role in prostate
tumorigenesis under our experimental conditions through
assessing levels of the protein expression via mass spec. Our
results indeed provided evidence that in addition to its roles
in metastatic capacity and intracellular, chemotherapy-
mediated apoptosis in prostate cancer cell lines, RKIP affects
the chemosensitivity of prostate cells. Through packaging in
EVs or by the transfer of factors that enhance proteinTable 4 Inflammation and immune response related
proteins found in the common proteins between patients
13, 14, 16, 18, and 19
Accession # Protein name
P10809 60 kDa heat shock protein, mitochondrial
P04083 Annexin A1
P08238 Heat shock protein HSP 90-beta
P32119 Peroxiredoxin-2
Using Gene Ontology (GO) terms, the common proteins between patients 13,
14, 16, 18, and 19 were filtered according to GO terms which are related to
inflammation and immune response.production, RKIP expression is induced or suppressed lead-
ing to chemosensitivity or chemoresisitance, respectively.
An increase in RKIP was observed from mass spec analysis
(Table 2) from patient samples co-cultured with PrECs.
Thus, the RKIP that is packaged in EVs provides another
chemotherapy or resistance mechanism that can be targeted.
Expression levels of RKIP are predictive of clinical outcome
as the level of metastasis in prostate cancer decreases as the
levels of RKIP expression increases. Through utilizing EVs
to modify the expression levels of RKIP in prostate cancer, it
is possible that the metastatic potential of tumor cells can be
targeted by an EV-mediated induction of RKIP. Further,P27797 Calreticulin
P04843 Dolichyl-diphosphooligosaccharide–protein
glycosyltransferase subunit 1
P68104 Elongation factor 1-alpha 1
P11142 Heat shock cognate 71 kDa protein
P32119 Peroxiredoxin-2
P35232 Prohibitin
P68371 Tubulin beta-4B chain
P13010 X-ray repair cross-complementing protein 5
Using Gene Ontology (GO) terms, the common proteins between patients 13,
14, 16, 18, and 19 were filtered according to GO terms which are related to
DNA transcription and translation.
Figure 7 Common proteins between patients 13, 14, 16, 18, and 19 and associated functions and canonical pathways. IPA analysis of the
71 common proteins between patients 13, 14, 16, 18, and 19. The bar graphs show the significance (−log(p-value)) of specific functions, A, and canonical
pathways, B, in each patient. The threshold cutoff of significance is p < 0.05 (or –log = 1.3).
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prostate cancer would likely also lead to apoptosis in target
cells. These findings suggest an additional role for RKIP in
tumorigenesis.
Our results further indicate that the in vitro recipient cells
of horizontally transferred genetic material, via EV co-
culture, have altered expression levels of STAT3, and
SOCS3. Signal transducer and activator of transcription 3
(STAT3) is a pro-survival protein responsible for the up-
regulation of proteins that promote cell proliferation and
growth [29,30]. During tumor development and subsequent
metastatic progression, the ability of tumors to invade the
lymphovascular system is mediated by STAT3 [31]. STAT
proteins are substrates for the proto-oncogene c-Src, and
can mediate c-Src’s biologic effects, which include
androgen-induced proliferation of prostate cancer and po-
tentially even the transition to androgen-independent
growth [32,33].Src is highly expressed in prostate cancer cell lines as well
as in the majority of prostate cancer specimens [32]. Main-
tenance of cancer cell proliferation and survival is mediated
by STAT3 even after sustained c-Src inhibition through the
activation of pro-survival genes, [34]. Hence, STAT3 has
been identified as an attractive target for prostate cancer,
where its activity is inherently activated. Inhibition of
STAT3, though disruption in activation or expression, leads
to cessation of tumor cell growth and apoptosis [29]. To
date, chemotherapeutic agents such as CPT have been
demonstrated to down-regulate STAT3 levels. Our data
suggests that EVs are immune to these limitations and can
effectively eliminate the effects of STAT3 mediated signal-
ing in prostate cancer. As shown in Figure 3, levels of
STAT3 are down-regulated, and levels of SOC3 are up-
regulated after the malignant DU145 cells are co-cultured
with non-malignant PrEC EVs (also shown in Table 1).
Suppressor of cytokine signaling 3 (SOCS3) plays a negative
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expression of the protein is adequate to prevent STAT3
activation [34]. The suppression of STAT3 suggests an en-
dogenous epigenetic mechanism that normal, non-
malignant cells produce to suppress STAT3-mediated cell
survival signaling.
Utilizing 2 patients with Gleason grade 8 indicated, via
mass spectrometry analysis, the enhanced RKIP and
prohibitin was upregulated to non-malignant PrECs
(Table 2). pRKIP is an inhibitor of RKIP function [35]
and allows Raf-mediated cancer cell survival to be en-
hanced. Prohibitin was originally identified as a putative
tumor suppressor protein that enhances p53 transcrip-
tion [36-38]. A recent study has demonstrated that
prohibitin proteins are necessary for the proliferation of
cancer cells [39]. Thus the induction/phosphorylation of
these proteins via EV-mediated transfer would promote
the change, a switch in phenotype to promote prostate
cell survival. Indeed our results from Figure 4 demon-
strate that PrECs have acquired the ability to signifi-
cantly grow in soft agar (p < 0.0005 and 0.0001) when
co-cultured independently with 2 Gleason grade 8 pa-
tients EVs. Our results provide preliminary insight into
putative mechanisms leading to phenotype switching of
normal tissue via EVs released from malignant adjacent
tissue.
14-3-3 proteins are a family of conserved regulatory
molecules expressed in all eukaryotic cells. 14-3-3 pro-
teins have the ability to bind a multitude of functionally
diverse signaling proteins, including kinases, phospha-
tases, and transmembrane receptors. It has been demon-
strated that expression of 14-3-3 proteins is significantly
elevated in multiple cancers [40,41]. Our proteomic and
IPA analysis determined the enhancement of 14-3-3
zeta/delta expression in our co-culture of patients 18,
and 19 EVs with PrEC cells (Figure 5). In addition, these
proteins along with 14-3-3 epsilon was determined to be
a common protein found between patients 13,14 and 16
(Tables 3, 4 and 5). In prostate cancer models, the inhib-
ition of PC3M cell growth was abrogated, in part, by the
suppression of 14-3-3 zeta/delta [42]. It has been shown
that 14-3-3zeta is an androgen-responsive gene that acti-
vates proliferation, cell survival, and androgen receptor
transcriptional activity and facilitate the progression of
prostate cancer [43]. Similarly, 14-3-3eta has been
shown to enhance androgen- and mitogen-induced an-
drogen receptor transcriptional activity in castration-
recurrent prostate cancer [44]. In contrast, 14-3-3σ
expression is down-regulated during the neoplastic tran-
sition of prostate epithelial cells [45] while there is epi-
genetic inactivation of 14-3-3σ occurs at an early stage
of prostate tumor development [46]. 14-3-3 proteins
complex with many signaling molecules, including
the Raf-1 kinase [47]. 14-3-3 beta and zeta can beassociated with Raf in mammalian cells and accompany
Raf to the cell membrane. Therefore, 14-3-3 proteins
may participate in or be required for the regulation of
Raf function [48]. Raf A, B, and C activity is differentially
regulated by its C-terminal and internal 14-3-3 binding
domain. In this model, prohibitin, acting as scaffold pro-
tein, affected C-RAF activation in a stimulatory manner
and interfered with the internal 14-3-3 binding site in C-
RAF [49]. Prohibitin-mediated activation of C-Raf at
membranes occurs by direct 14-3-3 displacement most
probably from the internal 14-3-3 binding site [49]. We
observe enhanced levels of prohibitin and 14-3-3 zeta/
delta in PrEC cells after co-culture with patient 18 and
19 EVs (Figure 5). Although prohibitin may displace 14-
3-3 zeta/delta from binding to Raf, 14-3-3 zeta/delta
could still stimulate androgen receptor-mediated growth
and prohibitin Raf-mediated MAPK signaling promoting
oncogenic growth of PrEC cells. Our results suggest that
14-3-3 proteins may provide a therapeutic target in
prostate cancer patients.
Conclusions
It is highly feasible that we could target tumor progres-
sion through utilizing EVs as a therapeutic agent or
tumor biomarker. The presence of EVs in cancer seem-
ingly aids in accelerating the genetic changes necessary
for tumor progression. Thus, probing the relationships
between the maintenance of normal and malignant
states and the import/export of proteins holds promise
towards unveiling the potential diagnostic and/or pre-
dictive nature of EVs in cancer. Indeed, our detection of
14-3-3 proteins and their subsequent enhanced protein
levels mediated by patient EVs provide a potential thera-
peutic target. Our intent is to establish EVs as indicators
of therapeutic effectiveness, disease recurrence or resist-
ance, and/or possible metastases. We are continuing our
studies to identify the content of EVs derived from nor-
mal and malignant prostate tissue, using the same
in vitro experimental approaches. We are expanding the
database from which we will obtain EVs to include dif-
ferent grades of prostate tumor specimens from a ra-
cially and ethnically diverse population of men.
Additional proteomic analysis should produce a compre-
hensive database of the proteins associated with EV
transfer including prostate-specific trafficking genes,
tumor cell surface markers, and other proteins that are
specifically associated with the pathogenesis of prostate
cancer. Despite the unresolved questions surrounding
extracellular vesicle density, content, and transport of
biological material cells between target cells, EVs could
have many direct clinical applications. The ability of EVs
to elicit phenotypic and genotypic changes in cancer
presents an opportunity to treat cancer through blocking
the transfer of genetic material by preventing EV release
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from accepting the EVs. Additionally, findings from
patient-based clinical samples could be implicated in de-
signing therapies not only directed towards the genetic/
epigenetic alterations common to all prostate cancers,
but also to those that are unique to each individual pa-
tients. Tailoring therapeutic intervention a priori form
knowledge of disease course would represent a powerful
clinical tool that could lead to improved outcomes and
reduced recurrence of prostate cancer.
Additional file
Additional file 1: Table S1. List of common proteins found in Patient
13, 14, and 16 EVs.
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